Longitudinal Restriction Spectrum Imaging Is Resistant to Pseudoresponse in Patients with High-Grade Gliomas Treated with Bevacizumab

被引:28
|
作者
Kothari, P. D. [1 ]
White, N. S. [2 ,5 ]
Farid, N. [2 ,5 ]
Chung, R. [2 ]
Kuperman, J. M. [2 ,5 ]
Girard, H. M. [5 ]
Shankaranarayanan, A. [7 ]
Kesari, S. [3 ,6 ]
McDonald, C. R. [4 ,5 ]
Dale, A. M. [2 ,3 ,4 ,5 ]
机构
[1] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA
[2] Univ Calif San Diego, Dept Radiol, La Jolla, CA 92093 USA
[3] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA
[4] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA
[5] Univ Calif San Diego, Multimodal Imaging Lab, La Jolla, CA 92093 USA
[6] Univ Calif San Diego, Moores Canc Ctr, Translat Neurooncol Labs, La Jolla, CA 92093 USA
[7] GE Healthcare, Milwaukee, WI USA
关键词
APPARENT DIFFUSION-COEFFICIENT; BRAIN-TUMORS; RESPONSE CRITERIA; ANTIANGIOGENIC THERAPY; GLIOBLASTOMA PATIENTS; MRI; VASCULATURE; SURVIVAL;
D O I
10.3174/ajnr.A3506
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BACKGROUND AND PURPOSE: Antiangiogenic therapies, such as bevacizumab, decrease contrast enhancement and FLAIR hyperintensity in patients with high-grade gliomas in a manner that may not correlate with actual tumor response. This study evaluated the ability of an advanced DWI technique, restriction spectrum imaging, to improve conspicuity within regions of restricted diffusion compared with ADC in patients treated with bevacizumab and to demonstrate that unlike ADC, restriction spectrum imaging is less affected by bevacizumab-induced reductions in FLAIR hyperintensity. MATERIALS AND METHODS: Restriction spectrum imaging cellularity maps and DWI were available for 12 patients with recurrent high-grade gliomas at baseline and following initiation of bevacizumab. VOIs were drawn for regions of restricted diffusion, surrounding FLAIR hyperintensity, and normal-appearing white matter; and intensity values within regions of restricted diffusion and FLAIR hyperintensity were normalized to normal-appearing white matter. Normalized values were compared between restriction spectrum imaging cellularity maps and ADC at baseline and on treatment by using repeated-measures ANOVA. RESULTS: All patients exhibited decreases in contrast enhancement and FLAIR hyperintensity following treatment. Normalized intensity values were higher on restriction spectrum imaging cellularity maps compared with ADC in regions of restricted diffusion, whereas intensity values were higher on ADC compared with restriction spectrum imaging cellularity maps in regions of FLAIR hyperintensity. Bevacizumab-induced decreases in FLAIR hyperintensity had a greater effect on ADC than on the restriction spectrum imaging cellularity maps, with the relative sensitivity of ADC to changes in FLAIR hyperintensity being >20 times higher than that on restriction spectrum imaging cellularity maps. CONCLUSIONS: Restriction spectrum imaging is less influenced by reductions in FLAIR hyperintensity compared with ADC, which may confer an advantage of restriction spectrum imaging over ADC for interpreting tumor response on imaging following antiangiogenic therapy.
引用
收藏
页码:1752 / 1757
页数:6
相关论文
共 50 条
  • [1] Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma
    McDonald, Carrie R.
    Delfanti, Rachel L.
    Krishnan, Anitha P.
    Leyden, Kelly M.
    Hattangadi-Gluth, Jona A.
    Seibert, Tyler M.
    Karunamuni, Roshan
    Elbe, Pia
    Kuperman, Joshua M.
    Bartsch, Hauke
    Piccioni, David E.
    White, Nathan S.
    Dale, Anders M.
    Farid, Nikdokht
    [J]. NEURO-ONCOLOGY, 2016, 18 (11) : 1579 - 1590
  • [2] MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy
    Pope, WB
    Lai, A
    Nghiemphu, P
    Mischel, P
    Cloughesy, TF
    [J]. NEUROLOGY, 2006, 66 (08) : 1258 - 1260
  • [3] MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy
    Chamberlain, Marc C.
    [J]. NEUROLOGY, 2006, 67 (11) : 2089 - 2089
  • [4] CALCIFICATION IN HIGH-GRADE GLIOMAS TREATED WITH BEVACIZUMAB
    Bokstein, Felix
    Aisenstein, Orna
    Ben-Bashat, Dafna
    Artzi, Moran
    Ram, Zvi
    Kanner, Andrew A.
    Corn, Benjamin
    Blumenthal, Deborah
    [J]. NEURO-ONCOLOGY, 2008, 10 (05) : 826 - 826
  • [5] PREDICTIVE VALUE OF CT AND MR PERFUSION IMAGING IN PATIENTS WITH HIGH-GRADE MALIGNANT GLIOMAS TREATED WITH BEVACIZUMAB
    Piludu, Francesca
    Pace, Andrea
    Fabi, Alessandra
    Anelli, Vincenzo
    Villani, Veronica
    Carapella, Carmine
    Marzi, Simona
    Vidiri, Antonello
    [J]. NEURO-ONCOLOGY, 2013, 15 : 201 - 201
  • [6] BEVACIZUMAB FOR RECURRENT HIGH-GRADE GLIOMAS
    Sahebjam, Solmaz
    Garoufalis, Evgenia
    Guiot, Marie Christine
    Muanza, Thierry
    Del Maestro, Ronaldo
    Kavan, Petr
    [J]. NEURO-ONCOLOGY, 2010, 12 : 43 - 43
  • [7] Bevacizumab in the treatment of high-grade gliomas: an overview
    Kunnakkat, Saroj
    Narayana, Ashwatha
    [J]. ANGIOGENESIS, 2011, 14 (04) : 423 - 430
  • [8] Bevacizumab in recurrence or progress of high-grade gliomas
    Maier, R.
    Eiter, H.
    Burger, R.
    De Vries, A.
    [J]. MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2009, 2 : 13 - 14
  • [9] Bevacizumab in the treatment of high-grade gliomas: an overview
    Saroj Kunnakkat
    Ashwatha Narayana
    [J]. Angiogenesis, 2011, 14 : 423 - 430
  • [10] Bevacizumab in recurrence or progress of high-grade gliomas
    R. Maier
    H. Eiter
    R. Burger
    A. De Vries
    [J]. memo - Magazine of European Medical Oncology, 2009, 2 (Suppl 3) : 13 - 14